We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cutting-Edge Lab Automation System Supports High-Volume Needs and Provides Faster Results

By LabMedica International staff writers
Posted on 19 Dec 2023
Print article
Image: The GLP systems Track is a total laboratory automation solution that meets high-volume needs (Photo courtesy of Abbott)
Image: The GLP systems Track is a total laboratory automation solution that meets high-volume needs (Photo courtesy of Abbott)

A new, innovative automation solution for clinical labs featuring smart technology can boost lab performance and flexibility, reduce turnaround time, and eliminate 80% of manual steps, thereby increasing reliability and minimizing errors to provide quicker lab results

Abbott’s (Lake Forest, IL, USA) GLP systems Track is a cutting-edge technology and scalable automation solution that helps laboratories meet high-volume demand and maximize productivity. This system introduces innovative features that boost safety, productivity, and capacity to meet increasing laboratory demands. The flexibility of the GLP systems Track is a standout feature, offering laboratories the ability to tailor the system’s configuration to their specific requirements. A key innovation in this system is the CAR, a smart, self-propelled single sample carrier, which allows samples to move independently, not attached to rigid, fixed mechanized track systems. This innovation minimizes mechanical breakdowns that could halt operations, ensuring continuous functionality and adaptability to the lab's evolving needs.

Laboratory results influence up to 70% of medical decisions, and Abbott’s GLP systems Track significantly enhances healthcare quality by automating laboratory processes and aiming to reduce healthcare costs. Its state-of-the-art technology streamlines and simplifies lab tasks. This automation solution transforms sample sorting and transportation, allowing for automatic sample movement throughout the system. It is tailored to meet each lab's unique requirements, effectively managing demand and boosting overall output. The system integrates seamlessly with lab staff workflows, enhancing efficiency and safeguarding lab worker health by reducing direct contact with patient blood samples and lessening exposure to biomedical waste. Capable of handling up to 25,000 test tubes daily across various care settings, this system improves patient test result turnaround times. It also aids in decreasing operational expenses and minimizing manual errors. Abbott's GLP systems Track has received approval from the U.S. Food and Drug Administration (FDA) and is now available in the United States.

“We know that our customers are seeking flexibility and scalability in their laboratory operations so they can meet ever-growing demand,” said Louis Morrone, executive vice president for Abbott’s core diagnostics business. “GLP systems Track addresses those needs, enabling labs to increase performance and improve the overall quality of their operations.”

Related Links:
Abbott

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.